Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-11-28
Study Completion Date
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Xlear have developed and patented a xylitol containing nasal spray for the treatment of upper-respiratory tract infections. The nasal spray is comprised of xylitol and GSE (Grapefruit Seed extract) which provides antibacterial properties as well as preventing viral adhesion in the nasal passage. Studies into Xlear's antiviral effects on SARS-CoV-2 are currently ongoing but hypothetically, a Xylitol Based Nasal spray may prove to be a useful and inexpensive treatment for COVID-19 infection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2
NCT04610801
Covid19
WITHDRAWN
PHASE3
A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection
NCT04858620
Covid19
WITHDRAWN
PHASE3
SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
NCT06048393
COVID-19
UNKNOWN
PHASE1
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
NCT04951349
Covid19
COMPLETED
PHASE2
A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold
NCT01488604
Common Cold
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1\. BACKGROUND and RATIONALE
In the wake of the Coronavirus disease 2019 (COVID-19) pandemic, worldwide healthcare has rapidly evolved in response. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for COVID-19, which at the most severe end of the spectrum of disease can require hospitalisation or ICU admission. Preventative measures are currently being taken with numerous vaccination programs across the world. However, there is currently no established treatment for mild COVID-19 infection, i.e., symptomatic infection not requiring hospitalisation, which makes up a significant proportion of cases. Xylitol has shown promising results in combating SARS-CoV-2 in vitro and this study aims to explore whether Xlear's Xylitol based Nasal Spray has an effect in vivo.
1.1 COVID-19 Infection SARS-CoV-2 is a positive-sense, single-strand RNA virus comprised of four structural proteins: Nucleocapsid (N) protein, Membrane (M) protein, Spike (S) protein and Envelope (E) protein. These structural proteins play an important role in receptor binding, transcription, replication and assembly of the virus in host cells (Boopathi et al., 2020). The nasal epithelium acts as the primary site for SARS-CoV-2 binding to angiotensin converting enzyme-2 (ACE2) - the receptor responsible for COVID-19 infection (Zhou et al., 2020). With nasal carriage playing a vital role in transmission, drugs administered intranasally could be a viable therapeutic option (Sungnak et al., 2020).
1.2 Drug: Xylitol Xylitol is a sugar alcohol derived from plants. It is used in the dental profession to prevent plaque build-up and inhibit enamel demineralisation by interfering with the metabolism of Streptococcus mutans, causing cell death and thus preventing dental caries (Janakiram et al., 2017). Xylitol not only demonstrates antimicrobial behaviour but can also modulate immunity and contribute to wound healing (Salli et al., 2019).
1.2.1 Xylitol and Respiratory Tract Infections Xylitol's inhibitory effect on Streptococcus mutans growth has prompted more research into its interactions with other nasopharyngeal pathogens responsible for respiratory tract infections. An in vitro study into alpha-haemolytic Streptococcus pneumoniae and beta-haemolytic Streptococci treated with 1% and 5% xylitol showed statistically significant inhibition of growth over a 24-hour incubation period (Kontiokari et al., 1999).
Another team established xylitol's ability to kill coagulase-negative Staphylococcus. 5% xylitol administered to 21 participants compared to a control group using a saline solution showed a significant decrease in Staphylococcus count from 597 colony forming units (CFU) per swab to 99 CFU per swab (Zabner et al., 2000).
1.2.2 Xylitol and Viruses Xylitol's inhibitory effects on bacteria are well documented but little is known regarding its antiviral properties. Dietary xylitol was used to treat influenza A virus in vivo. Mice given a combination of xylitol and red ginseng had 100% survival rate at 33mg/kg/day of xylitol and 60% survival rate at 3.3mg/kg/day after day 14 of infection versus 0% survival rate on PBS (control), red ginseng and xylitol separately. This suggests a synergistic effect between xylitol and red ginseng (Yin et al., 2014).
A study into xylitol and its interactions with human respiratory syncytial virus (hRSV) was conducted in 2015. Xylitol was tested in vitro on a hRSV suspension and in vivo in mice. The in vitro effect of xylitol showed complete inhibition at concentrations of 3.13mg/ml. Xylitol significantly reduced lung viral titres in mice with 3.3mg/kg/d proving the most effective dose (Xu et al., 2016).
1.3 Grapefruit Seed Extract (GSE) Grapefruit seed extract (GSE) is made from grapefruit seeds. It is used as a natural remedy due to its antioxidant and antimicrobial properties (Reagor et al., 2002; Salehi et al., 2019).
1.3.1 GSE and Viruses GSE was tested on multiple viruses to determine if it had any inhibitory effects. GSE exhibited virucidal activity against avian influenza virus (AIV) and Newcastle disease virus (NDV) but not against infectious bursal disease virus (IBDV) (Komura et al., 2019). These findings may be important as AIV and NDV are enveloped viruses like SARS-CoV-2 whilst IBDV is not (Schoeman et al., 2019). It could be hypothesised that GSE could exhibit similar inhibition on SARS-CoV-2.
1.4 Xlear's Xylitol based Nasal Spray Xlear have developed and patented a xylitol containing nasal spray for the treatment of upper-respiratory tract infections. The nasal spray is comprised of xylitol and GSE which provides antibacterial properties as well as preventing viral adhesion in the nasal passage. Studies into Xlear's antiviral effects on SARS-CoV-2 are currently ongoing but hypothetically, a Xylitol Based Nasal spray may prove to be a useful and inexpensive treatment for COVID-19 infection.
1.4.1 Xlear and Coronavirus Xylitol has been shown to exhibit antiviral properties against SARS-CoV-2 in vitro (Bansal et al., 2021; Ferrer et al., 2020).
USA-WAI/2020 strain was prepared and passaged in Vero 76 cells for testing with Xlear (experiment 2) and its components xylitol and GSE separately (experiment 1). GSE 0.2% reduced SARS-CoV-2 from 3.67 log10 CCID50/0.1 mL to undetectable in experiment 1. Xlear in virucidal assays completely inhibited viral infectively at varying concentrations (90%, 80%, 50%) and reduced viral titre by 2.17 log in 20% concentration indicating a dose-dependent response (Appendix 1) (Ferrer et al., 2020). A subsequent study showed statistically significant reduction in viral titres treated with Xlear nasal spray treatment - 4.2 log10 CCID50/0.1mL to 1.7, a reduction of 2.5 log10 CCID50 (Cannon et al., 2020).
A recent private report by Dr Cagno's team in Lausanne (April 2021) has confirmed the viral killing properties of Xlear in 2021 SARS-CoV-2 strains. Viral stocks were grown in Vero E6 cells belonging to two lineages, B1.1.7 and B1.351. Complete inhibition of viral infectivity was observed in 90%, 60% and 20% concentration Xlear virucidal assays for B1.351. Viral infectivity was similarly completely inhibited in B1.17 at 90% and 60% concentration with a 3.06 log reduction at 20% illustrated in Appendix 2.
A case study was conducted on individuals who had taken Xlear as treatment for COVID-19 infection. Participants were required to spray into each nostril four times per day (140 µL per spray). All individuals showed improvement in symptoms with quicker turnarounds from turning positive to negative via COVID-19 reverse transcriptase polymerase chain reaction (RT-PCR) nasal swabs. Importantly, some individuals had relevant co-morbidities such as current smoking status and obesity. Although it is difficult to attribute symptom improvement and viral load decrease to Xlear's spray, it does provide rationale for a double-blind placebo controlled randomised clinical trial (Go et al., 2020).
In the wake of the Coronavirus disease 2019 (COVID-19) pandemic, worldwide healthcare has rapidly evolved in response. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for COVID-19, which at the most severe end of the spectrum of disease can require hospitalisation or ICU admission. Preventative measures are currently being taken with numerous vaccination programs across the world. However, there is currently no established treatment for mild COVID-19 infection, i.e., symptomatic infection not requiring hospitalisation, which makes up a significant proportion of cases. Xylitol has shown promising results in combating SARS-CoV-2 in vitro and this study aims to explore whether Xlear's Xylitol based Nasal Spray has an effect in vivo.
1.1 COVID-19 Infection SARS-CoV-2 is a positive-sense, single-strand RNA virus comprised of four structural proteins: Nucleocapsid (N) protein, Membrane (M) protein, Spike (S) protein and Envelope (E) protein. These structural proteins play an important role in receptor binding, transcription, replication and assembly of the virus in host cells (Boopathi et al., 2020). The nasal epithelium acts as the primary site for SARS-CoV-2 binding to angiotensin converting enzyme-2 (ACE2) - the receptor responsible for COVID-19 infection (Zhou et al., 2020). With nasal carriage playing a vital role in transmission, drugs administered intranasally could be a viable therapeutic option (Sungnak et al., 2020).
1.2 Drug: Xylitol Xylitol is a sugar alcohol derived from plants. It is used in the dental profession to prevent plaque build-up and inhibit enamel demineralisation by interfering with the metabolism of Streptococcus mutans, causing cell death and thus preventing dental caries (Janakiram et al., 2017). Xylitol not only demonstrates antimicrobial behaviour but can also modulate immunity and contribute to wound healing (Salli et al., 2019).
1.2.1 Xylitol and Respiratory Tract Infections Xylitol's inhibitory effect on Streptococcus mutans growth has prompted more research into its interactions with other nasopharyngeal pathogens responsible for respiratory tract infections. An in vitro study into alpha-haemolytic Streptococcus pneumoniae and beta-haemolytic Streptococci treated with 1% and 5% xylitol showed statistically significant inhibition of growth over a 24-hour incubation period (Kontiokari et al., 1999).
Another team established xylitol's ability to kill coagulase-negative Staphylococcus. 5% xylitol administered to 21 participants compared to a control group using a saline solution showed a significant decrease in Staphylococcus count from 597 colony forming units (CFU) per swab to 99 CFU per swab (Zabner et al., 2000).
1.2.2 Xylitol and Viruses Xylitol's inhibitory effects on bacteria are well documented but little is known regarding its antiviral properties. Dietary xylitol was used to treat influenza A virus in vivo. Mice given a combination of xylitol and red ginseng had 100% survival rate at 33mg/kg/day of xylitol and 60% survival rate at 3.3mg/kg/day after day 14 of infection versus 0% survival rate on PBS (control), red ginseng and xylitol separately. This suggests a synergistic effect between xylitol and red ginseng (Yin et al., 2014).
A study into xylitol and its interactions with human respiratory syncytial virus (hRSV) was conducted in 2015. Xylitol was tested in vitro on a hRSV suspension and in vivo in mice. The in vitro effect of xylitol showed complete inhibition at concentrations of 3.13mg/ml. Xylitol significantly reduced lung viral titres in mice with 3.3mg/kg/d proving the most effective dose (Xu et al., 2016).
1.3 Grapefruit Seed Extract (GSE) Grapefruit seed extract (GSE) is made from grapefruit seeds. It is used as a natural remedy due to its antioxidant and antimicrobial properties (Reagor et al., 2002; Salehi et al., 2019).
1.3.1 GSE and Viruses GSE was tested on multiple viruses to determine if it had any inhibitory effects. GSE exhibited virucidal activity against avian influenza virus (AIV) and Newcastle disease virus (NDV) but not against infectious bursal disease virus (IBDV) (Komura et al., 2019). These findings may be important as AIV and NDV are enveloped viruses like SARS-CoV-2 whilst IBDV is not (Schoeman et al., 2019). It could be hypothesised that GSE could exhibit similar inhibition on SARS-CoV-2.
1.4 Xlear's Xylitol based Nasal Spray Xlear have developed and patented a xylitol containing nasal spray for the treatment of upper-respiratory tract infections. The nasal spray is comprised of xylitol and GSE which provides antibacterial properties as well as preventing viral adhesion in the nasal passage. Studies into Xlear's antiviral effects on SARS-CoV-2 are currently ongoing but hypothetically, a Xylitol Based Nasal spray may prove to be a useful and inexpensive treatment for COVID-19 infection.
1.4.1 Xlear and Coronavirus Xylitol has been shown to exhibit antiviral properties against SARS-CoV-2 in vitro (Bansal et al., 2021; Ferrer et al., 2020).
USA-WAI/2020 strain was prepared and passaged in Vero 76 cells for testing with Xlear (experiment 2) and its components xylitol and GSE separately (experiment 1). GSE 0.2% reduced SARS-CoV-2 from 3.67 log10 CCID50/0.1 mL to undetectable in experiment 1. Xlear in virucidal assays completely inhibited viral infectively at varying concentrations (90%, 80%, 50%) and reduced viral titre by 2.17 log in 20% concentration indicating a dose-dependent response (Appendix 1) (Ferrer et al., 2020). A subsequent study showed statistically significant reduction in viral titres treated with Xlear nasal spray treatment - 4.2 log10 CCID50/0.1mL to 1.7, a reduction of 2.5 log10 CCID50 (Cannon et al., 2020).
A recent private report by Dr Cagno's team in Lausanne (April 2021) has confirmed the viral killing properties of Xlear in 2021 SARS-CoV-2 strains. Viral stocks were grown in Vero E6 cells belonging to two lineages, B1.1.7 and B1.351. Complete inhibition of viral infectivity was observed in 90%, 60% and 20% concentration Xlear virucidal assays for B1.351. Viral infectivity was similarly completely inhibited in B1.17 at 90% and 60% concentration with a 3.06 log reduction at 20% illustrated in Appendix 2.
A case study was conducted on individuals who had taken Xlear as treatment for COVID-19 infection. Participants were required to spray into each nostril four times per day (140 µL per spray). All individuals showed improvement in symptoms with quicker turnarounds from turning positive to negative via COVID-19 reverse transcriptase polymerase chain reaction (RT-PCR) nasal swabs. Importantly, some individuals had relevant co-morbidities such as current smoking status and obesity. Although it is difficult to attribute symptom improvement and viral load decrease to Xlear's spray, it does provide rationale for a double-blind placebo controlled randomised clinical trial (Go et al., 2020).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Respiratory Viral Infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Randomization to Nasal Spray or Placebo
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Subjects will be randomized 1:1 to receive the Xylitol Based Nasal Spray or a matching saline base placebo. This is a double blinded study. The Nasal Spray Kits will be randomized and allocated to patients in chronological order.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional
The participants will receive Xylitol based nasal spray
Group Type
EXPERIMENTAL
Nasal Spray
Intervention Type
DEVICE
The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
Control
The participants will receive saline based placebo
Group Type
PLACEBO_COMPARATOR
Nasal Spray
Intervention Type
DEVICE
The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nasal Spray
The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Xlear nasal spray
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol;
* Adult aged ≥18 years old with at least two comorbidities: diabetes (type 1 \&2), obesity (BMI \>30), hypertension, chronic heart disease, chronic pulmonary disease, chronic liver disease.
* Internet access and capability and willingness to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period;
* COVID-19 infection confirmed with a laboratory SARS-CoV-2 RT-PCR nasal swab;
* Specimen collected within the past 48 hours;
* Mild COVID-19 symptoms which may include fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath
* Adult aged ≥18 years old with at least two comorbidities: diabetes (type 1 \&2), obesity (BMI \>30), hypertension, chronic heart disease, chronic pulmonary disease, chronic liver disease.
* Internet access and capability and willingness to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period;
* COVID-19 infection confirmed with a laboratory SARS-CoV-2 RT-PCR nasal swab;
* Specimen collected within the past 48 hours;
* Mild COVID-19 symptoms which may include fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath
Exclusion Criteria
* Not fit to consent and unable to follow the protocol;
* Age \<18 years;
* Current tracheostomy or laryngectomy;
* Hypersensitivity to the active substance or to any of the excipients;
* Concomitant respiratory therapy such as oxygen or ventilator support. Positive airway pressure for obstructive sleep apnea is permitted if treatment was established with good compliance at least 3 months before enrolment;
* Need for hospitalisation for any reason;
* Inability to safely self-administer nasal spray
* Any clinical contraindications, as judged by the Qualified Medical Practitioner;
* Clinical signs indicative of moderate, severe or critical COVID severity symptoms (as defined by FDA COVID-19 Guidance Document)
* Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study;
* Lactating, pregnant or planning to become pregnant during the study period;
* Diagnosed with prior COVID-19 infection (\>48 hours from the time the test is reported prior to the time of screening).
* No relevant comorbidity or only one comorbidity
* Age \<18 years;
* Current tracheostomy or laryngectomy;
* Hypersensitivity to the active substance or to any of the excipients;
* Concomitant respiratory therapy such as oxygen or ventilator support. Positive airway pressure for obstructive sleep apnea is permitted if treatment was established with good compliance at least 3 months before enrolment;
* Need for hospitalisation for any reason;
* Inability to safely self-administer nasal spray
* Any clinical contraindications, as judged by the Qualified Medical Practitioner;
* Clinical signs indicative of moderate, severe or critical COVID severity symptoms (as defined by FDA COVID-19 Guidance Document)
* Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study;
* Lactating, pregnant or planning to become pregnant during the study period;
* Diagnosed with prior COVID-19 infection (\>48 hours from the time the test is reported prior to the time of screening).
* No relevant comorbidity or only one comorbidity
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metanoic Health Ltd.
INDUSTRY
Sponsor Role
collaborator
Xlear, Inc
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahsan W Rathore, MBBS
Role: PRINCIPAL_INVESTIGATOR
University of Health Sciences Lahore
Saqib Mahmood, MBBS PhD
Role: PRINCIPAL_INVESTIGATOR
University of Health Sciences Lahore
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Bansal S, Jonsson CB, Taylor SL, Figueroa JM, Dugour AV, Palacios C, Vega JC. Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. PLoS One. 2021 Nov 19;16(11):e0259943. doi: 10.1371/journal.pone.0259943. eCollection 2021.
Reference Type
RESULT
Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2021 Jun;39(9):3409-3418. doi: 10.1080/07391102.2020.1758788. Epub 2020 Apr 30.
Reference Type
RESULT
Go CC, Pandav K, Sanchez-Gonzalez MA, Ferrer G. Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series. Cureus. 2020 Nov 3;12(11):e11315. doi: 10.7759/cureus.11315.
Reference Type
RESULT
He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM. Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 Sep;26(9):1491-1493. doi: 10.1038/s41591-020-1016-z.
Reference Type
RESULT
Janakiram C, Deepan Kumar CV, Joseph J. Xylitol in preventing dental caries: A systematic review and meta-analyses. J Nat Sci Biol Med. 2017 Jan-Jun;8(1):16-21. doi: 10.4103/0976-9668.198344.
Reference Type
RESULT
Komura M, Suzuki M, Sangsriratanakul N, Ito M, Takahashi S, Alam MS, Ono M, Daio C, Shoham D, Takehara K. Inhibitory effect of grapefruit seed extract (GSE) on avian pathogens. J Vet Med Sci. 2019 Mar 30;81(3):466-472. doi: 10.1292/jvms.18-0754. Epub 2019 Feb 4.
Reference Type
RESULT
Kontiokari T, Uhari M, Koskela M. Effect of xylitol on growth of nasopharyngeal bacteria in vitro. Antimicrob Agents Chemother. 1995 Aug;39(8):1820-3. doi: 10.1128/AAC.39.8.1820.
Reference Type
RESULT
Salehi B, Fokou PVT, Sharifi-Rad M, Zucca P, Pezzani R, Martins N, Sharifi-Rad J. The Therapeutic Potential of Naringenin: A Review of Clinical Trials. Pharmaceuticals (Basel). 2019 Jan 10;12(1):11. doi: 10.3390/ph12010011.
Reference Type
RESULT
Salli K, Lehtinen MJ, Tiihonen K, Ouwehand AC. Xylitol's Health Benefits beyond Dental Health: A Comprehensive Review. Nutrients. 2019 Aug 6;11(8):1813. doi: 10.3390/nu11081813.
Reference Type
RESULT
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019 May 27;16(1):69. doi: 10.1186/s12985-019-1182-0.
Reference Type
RESULT
Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. Clin Infect Dis. 2020 Nov 19;71(16):2252-2254. doi: 10.1093/cid/ciaa619. No abstract available.
Reference Type
RESULT
Tu YP, O'Leary TJ. Testing for Severe Acute Respiratory Syndrome-Coronavirus 2: Challenges in Getting Good Specimens, Choosing the Right Test, and Interpreting the Results. Crit Care Med. 2020 Nov;48(11):1680-1689. doi: 10.1097/CCM.0000000000004594.
Reference Type
RESULT
Xu ML, Wi GR, Kim HJ, Kim HJ. Ameliorating Effect of Dietary Xylitol on Human Respiratory Syncytial Virus (hRSV) Infection. Biol Pharm Bull. 2016;39(4):540-6. doi: 10.1248/bpb.b15-00773.
Reference Type
RESULT
Yin SY, Kim HJ, Kim HJ. Protective effect of dietary xylitol on influenza A virus infection. PLoS One. 2014 Jan 2;9(1):e84633. doi: 10.1371/journal.pone.0084633. eCollection 2014.
Reference Type
RESULT
Zabner J, Seiler MP, Launspach JL, Karp PH, Kearney WR, Look DC, Smith JJ, Welsh MJ. The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11614-9. doi: 10.1073/pnas.97.21.11614.
Reference Type
RESULT
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Dec;588(7836):E6. doi: 10.1038/s41586-020-2951-z. No abstract available.
Reference Type
RESULT
Reagor L, Gusman J, McCoy L, Carino E, Heggers JP. The effectiveness of processed grapefruit-seed extract as an antibacterial agent: I. An in vitro agar assay. J Altern Complement Med. 2002 Jun;8(3):325-32. doi: 10.1089/10755530260128014.
Reference Type
RESULT
Sungnak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M, Talavera-Lopez C, Maatz H, Reichart D, Sampaziotis F, Worlock KB, Yoshida M, Barnes JL; HCA Lung Biological Network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020 May;26(5):681-687. doi: 10.1038/s41591-020-0868-6. Epub 2020 Apr 23.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
http://www.biorxiv.org/content/10.1101/2020.12.02.408575v3.abstract
Cannon, M., Westover, J., Bleher, R., Sanchez-Gonzalez, M. and Ferrer, G. In Vitro Analysis of the Anti-viral Potential of nasal spray constituents against SARS-CoV-2. bioRxiv, 2020. doi/10.1101/2020.12.02.408575
http://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.abstract
Ferrer, G., Betancourt, A., Go, C., Vazquez, H., Westover, J., Cagno, V., Tapparel, C. and Sanchez-Gonzalez, M. A Nasal Spray Solution of Grapefruit Seed Extract plus Xylitol Displays Virucidal Activity Against SARS-Cov-2 In Vitro. bioRxiv
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-XYLNS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection
NCT04443868
WITHDRAWN
PHASE2
Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
NCT05109611
TERMINATED
PHASE3
A Study to Determine the Tolerability of Intranasal LMN-301
NCT06030414
COMPLETED
PHASE1
A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients
NCT05659602
COMPLETED
NA
Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum
NCT04916574
COMPLETED
NA
Efficacy of Two Nasal Products Based on Diluted Seawater in the Treatment of Upper Respiratory Infections/Conditions
NCT06498843
NOT_YET_RECRUITING
NA
Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis
NCT05180500
COMPLETED
PHASE1
The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity
NCT00790972
WITHDRAWN
NA
PMCF Study to Evaluate Performance and Safety of "NASAL SPRAYS " Used to Relieve Nasal Congestion and Dryness
NCT05843071
COMPLETED
NA
PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray
NCT05122260
COMPLETED
PHASE1
A Study to Compare Two Formulations of Xylometazoline/Dexpanthenol Nasal Spray for the Treatment of Nasal Congestion.
NCT03439436
COMPLETED
PHASE3
Market Potential of Carbon Dioxide Nasal Spray
NCT02113449
COMPLETED
PHASE2
Intranasal Heparin Tolerability Study
NCT04490239
COMPLETED
EARLY_PHASE1
Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)
NCT00480194
COMPLETED
Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants
NCT02832362
COMPLETED
PHASE1
Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia
NCT04873141
COMPLETED
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
NCT05069610
COMPLETED
PHASE1/PHASE2
Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19
NCT05599919
COMPLETED
PHASE3
Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults
NCT04672291
COMPLETED
PHASE1
A Randomized Controlled Clinical Trial on the Use of Saline Nasal Irrigations to Eradicate Localized Nasal Infection by SARS-CoV-2
NCT05458336
COMPLETED
NA
Xylitol for Chronic Sinusitis
NCT03229551
COMPLETED
PHASE2/PHASE3
Nasal Irrigation to Reduce COVID-19 Morbidity
NCT04559035
COMPLETED
NA
Intranasal Lavage With Hypochlorous Acid Safely Reduces the Symptoms in the Ambulatory Patient With COVID-19.
NCT05950295
COMPLETED
Xylitol Versus Saline in Chronic Sinusitis
NCT00924404
COMPLETED
NA